FIELD: medicine.
SUBSTANCE: the present innovation deals with stable peroral solid composition of ramosetron or its pharmaceutically acceptable salt. The composition includes one or several components chosen out of the groups including aliphatic carboxylic acid or its ester, hydroxycarboxylic acid or its ester, acidic amino acid, enolic acid, aromatic carboxylic compound or its ester and high-molecular substance that contains carboxylic group. Such an innovation refers to the method for stabilizing ramosetron composition. The suggested innovation provides stability of ramosetron composition under conditions of increased temperature and humidity, especially at low content of active component.
EFFECT: higher efficiency of application.
14 cl, 10 ex, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICATION FOR TREATMENT OF IRRITATE BOWELS SYNDROME WITH DIARRHEA PREVALENCE | 2007 |
|
RU2351327C2 |
| MEANS FOR TREATING IRRITATED INTESTINE SYNDROME CASES WITH DIARRHEA PREDOMINANCE | 2005 |
|
RU2314808C2 |
| NEW PHARMACEUTICAL COMPOSITION OF TAMSULOZIN AND DUTASTERIDE | 2019 |
|
RU2795928C2 |
| SOLIFENACIN COMPOSITION OR ITS SALTS FOR USE IN SOLID PREPARATION | 2005 |
|
RU2359670C2 |
| PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH MASKED TASTE AND PREPARATION METHOD THEREOF | 2012 |
|
RU2583935C2 |
| METHOD OF ANTIDEMENTIA DRUG STABILISATION | 2005 |
|
RU2401125C2 |
| MISUSE PROTECTED DOSAGE FORM FOR OXIDATION SENSITIVE OPIOIDS | 2010 |
|
RU2555531C2 |
| MODIFIED RELEASE PHARMACEUTICAL COMPOSITION | 2009 |
|
RU2495666C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING NILOTINIB OR ITS SALTS | 2007 |
|
RU2469707C2 |
